Multidrug-resistant pathogens and ventilator-associated pneumonia in critically ill COVID-19 and non-COVID-19 patients: a prospective observational monocentric comparative study.
Antimicrobial resistance
COVID-19
Critical care
Difficult to treat organisms
Multidrug resistant organisms
Ventilator-acquired pneumonia
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
18 Apr 2024
18 Apr 2024
Historique:
received:
28
11
2023
accepted:
15
03
2024
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
18
4
2024
Statut:
epublish
Résumé
The COVID-19 pandemic has increased the incidence of ventilator-associated pneumonia (VAP) among critically ill patients. However, a comparison of VAP incidence in COVID-19 and non-COVID-19 cohorts, particularly in a context with a high prevalence of multidrug-resistant (MDR) organisms, is lacking. We conducted a single-center, mixed prospective and retrospective cohort study comparing COVID-19 patients admitted to the intensive care unit (ICU) of the "Città della Salute e della Scienza" University Hospital in Turin, Italy, between March 2020 and December 2021 (COVID-19 group), with a historical cohort of ICU patients admitted between June 2016 and March 2018 (NON-COVID-19 group). The primary objective was to define the incidence of VAP in both cohorts. Secondary objectives were to evaluate the microbial cause, resistance patters, risk factors and impact on 28 days, ICU and in-hospital mortality, duration of ICU stay, and duration of hospitalization). We found a significantly higher incidence of VAP (51.9% - n = 125) among the 241 COVID-19 patients compared to that observed (31.2% - n = 78) among the 252 NON-COVID-19 patients. The median SOFA score was significantly lower in the COVID-19 group (9, Interquartile range, IQR: 7-11 vs. 10, IQR: 8-13, p < 0.001). The COVID-19 group had a higher prevalence of Gram-positive bacteria-related VAP (30% vs. 9%, p < 0.001), but no significant difference was observed in the prevalence of difficult-to-treat (DTR) or MDR bacteria. ICU and in-hospital mortality in the COVID-19 and NON-COVID-19 groups were 71% and 74%, vs. 33% and 43%, respectively. The presence of COVID-19 was significantly associated with an increased risk of 28-day all-cause hospital mortality (Hazard ratio, HR: 7.95, 95% Confidence Intervals, 95% CI: 3.10-20.36, p < 0.001). Tracheostomy and a shorter duration of mechanical ventilation were protective against 28-day mortality, while dialysis and a high SOFA score were associated with a higher risk of 28-day mortality. COVID-19 patients with VAP appear to have a significantly higher ICU and in-hospital mortality risk regardless of the presence of MDR and DTR pathogens. Tracheostomy and a shorter duration of mechanical ventilation appear to be associated with better outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
The COVID-19 pandemic has increased the incidence of ventilator-associated pneumonia (VAP) among critically ill patients. However, a comparison of VAP incidence in COVID-19 and non-COVID-19 cohorts, particularly in a context with a high prevalence of multidrug-resistant (MDR) organisms, is lacking.
MATERIAL AND METHODS
METHODS
We conducted a single-center, mixed prospective and retrospective cohort study comparing COVID-19 patients admitted to the intensive care unit (ICU) of the "Città della Salute e della Scienza" University Hospital in Turin, Italy, between March 2020 and December 2021 (COVID-19 group), with a historical cohort of ICU patients admitted between June 2016 and March 2018 (NON-COVID-19 group). The primary objective was to define the incidence of VAP in both cohorts. Secondary objectives were to evaluate the microbial cause, resistance patters, risk factors and impact on 28 days, ICU and in-hospital mortality, duration of ICU stay, and duration of hospitalization).
RESULTS
RESULTS
We found a significantly higher incidence of VAP (51.9% - n = 125) among the 241 COVID-19 patients compared to that observed (31.2% - n = 78) among the 252 NON-COVID-19 patients. The median SOFA score was significantly lower in the COVID-19 group (9, Interquartile range, IQR: 7-11 vs. 10, IQR: 8-13, p < 0.001). The COVID-19 group had a higher prevalence of Gram-positive bacteria-related VAP (30% vs. 9%, p < 0.001), but no significant difference was observed in the prevalence of difficult-to-treat (DTR) or MDR bacteria. ICU and in-hospital mortality in the COVID-19 and NON-COVID-19 groups were 71% and 74%, vs. 33% and 43%, respectively. The presence of COVID-19 was significantly associated with an increased risk of 28-day all-cause hospital mortality (Hazard ratio, HR: 7.95, 95% Confidence Intervals, 95% CI: 3.10-20.36, p < 0.001). Tracheostomy and a shorter duration of mechanical ventilation were protective against 28-day mortality, while dialysis and a high SOFA score were associated with a higher risk of 28-day mortality.
CONCLUSION
CONCLUSIONS
COVID-19 patients with VAP appear to have a significantly higher ICU and in-hospital mortality risk regardless of the presence of MDR and DTR pathogens. Tracheostomy and a shorter duration of mechanical ventilation appear to be associated with better outcomes.
Identifiants
pubmed: 38637766
doi: 10.1186/s12931-024-02779-1
pii: 10.1186/s12931-024-02779-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
168Informations de copyright
© 2024. The Author(s).
Références
Respiration. 2006;73(4):503-8
pubmed: 16205047
Intensive Care Med. 2018 Dec;44(12):2216-2218
pubmed: 29797028
Front Pediatr. 2019 May 22;7:204
pubmed: 31192174
Intensive Care Med. 2020 May;46(5):888-906
pubmed: 32157357
Ann Intensive Care. 2020 Nov 23;10(1):158
pubmed: 33230710
ASAIO J. 2021 Jun 1;67(6):601-610
pubmed: 33965970
Eur Respir J. 2017 Sep 10;50(3):
pubmed: 28890434
BMC Pulm Med. 2021 Jan 30;21(1):47
pubmed: 33516213
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Curr Opin Infect Dis. 2022 Apr 1;35(2):149-162
pubmed: 35125396
Crit Care. 2021 Feb 18;25(1):72
pubmed: 33602296
Crit Care. 2007;11(4):R80
pubmed: 17640384
J Clin Med. 2023 Feb 06;12(4):
pubmed: 36835834
Crit Care. 2021 May 25;25(1):177
pubmed: 34034777
Chest. 2021 Aug;160(2):454-465
pubmed: 33857475
J Clin Med. 2021 Jun 16;10(12):
pubmed: 34208672
Crit Care. 2021 Jun 7;25(1):197
pubmed: 34099016
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Antibiotics (Basel). 2021 May 07;10(5):
pubmed: 34067186
Anesthesiology. 2003 Aug;99(2):275-82
pubmed: 12883399
Ann Transl Med. 2018 Nov;6(21):427
pubmed: 30581835
Crit Care. 2021 Jan 11;25(1):25
pubmed: 33430915
Intensive Crit Care Nurs. 2022 Jun;70:103227
pubmed: 35249794
J Glob Antimicrob Resist. 2020 Dec;23:398-400
pubmed: 33242674
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
J Infect Chemother. 2021 Jun;27(6):826-833
pubmed: 33583739
J Anesth Analg Crit Care. 2022 Aug 19;2(1):36
pubmed: 37386603
Intensive Care Med. 2021 Feb;47(2):188-198
pubmed: 33388794
Intensive Care Med. 2019 Sep;45(9):1312-1314
pubmed: 31267196
J Clin Med. 2022 Sep 02;11(17):
pubmed: 36079137
Curr Opin Crit Care. 2022 Feb 1;28(1):74-82
pubmed: 34932525
Lancet. 2009 Oct 17;374(9698):1351-63
pubmed: 19762075
Crit Care. 2020 Dec 18;24(1):699
pubmed: 33339526
J Clin Med. 2021 Feb 03;10(4):
pubmed: 33546093
Ther Drug Monit. 1993 Aug;15(4):263-6
pubmed: 8236359
Ann Intensive Care. 2021 Jan 29;11(1):20
pubmed: 33512602